Literature DB >> 33704078

Context and Barriers to the Prescription of Nonoccupational Postexposure Prophylaxis Among HIV Medical Care Providers: National Internet-Based Observational Study in China.

Haibo Ding1,2,3,4, Zehao Ye1,2,3,4, Junjie Xu1,2,3,4, Hong Shang1,2,3,4, Weiming Tang5, Xiaojie Huang6, Hui Wang7, Sitong Cui1,2,3,4, Yongjun Jiang1,2,3,4, Wenqing Geng1,2,3,4.   

Abstract

BACKGROUND: Nonoccupational postexposure prophylaxis (nPEP) is an effective HIV biomedical prevention strategy. The research and use of nPEP are mainly concentrated in the developed world, while little is known about the knowledge, attitudes, and practices of nPEP among HIV medical care providers in developing countries.
OBJECTIVE: We aimed to assess the nPEP knowledge and prescribing practice among HIV medical care providers in mainland China.
METHODS: HIV medical care providers were recruited in China during May and June 2019 through an online survey regarding nPEP-related knowledge, attitudes, and clinical prescription experiences. Multivariable logistic regression was performed to identify factors associated with prescribing nPEP among HIV medical care providers.
RESULTS: A total of 777 eligible participants participated in this study from 133 cities in 31 provinces in China. Of the participants, 60.2% (468/777) were unfamiliar with nPEP and only 53.3% (414/777) of participants ever prescribed nPEP. HIV care providers who worked in a specialized infectious disease hospital (vs general hospital, adjusted odds ratio [aOR] 2.49; 95% CI 1.85-3.37), had practiced for 6-10 years (vs 5 or fewer years, aOR 3.28; 95% CI 2.23-4.80), had practiced for 11 years or more (vs 5 or fewer years, aOR 3.75; 95% CI 2.59-5.45), and had previously prescribed occupational PEP (oPEP, aOR 4.90; 95% CI 3.29-7.29) had a significantly positive association with prescribing nPEP. However, unfamiliarity with nPEP (aOR 0.08; 95% CI 0.05-0.11), believing nPEP may promote HIV high-risk behavior (aOR 0.53; 95% CI 0.36-0.77) or result in HIV drug resistance (aOR 0.53; 95% CI 0.36-0.77) among key populations, and self-reported having no written oPEP guideline in place (aOR 0.53; 95% CI 0.35-0.79) were negatively associated with nPEP prescription behavior.
CONCLUSIONS: HIV medical care providers have insufficient nPEP knowledge and an inadequate proportion of prescribing, which may impede the scale-up of nPEP services to curb HIV acquisition. The implementation of tailored nPEP training or retraining to HIV medical care providers would improve this situation. ©Haibo Ding, Zehao Ye, Weiming Tang, Xiaojie Huang, Hui Wang, Sitong Cui, Yongjun Jiang, Wenqing Geng, Junjie Xu, Hong Shang. Originally published in JMIR Public Health and Surveillance (http://publichealth.jmir.org), 11.03.2021.

Entities:  

Keywords:  China; HIV medical care providers; WeChat; barrier; internet; key populations; nonoccupational postexposure prophylaxis (nPEP); prophylaxis; social media; training

Year:  2021        PMID: 33704078      PMCID: PMC7995069          DOI: 10.2196/24234

Source DB:  PubMed          Journal:  JMIR Public Health Surveill        ISSN: 2369-2960


  21 in total

1.  Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services.

Authors:  Dawn K Smith; Lisa A Grohskopf; Roberta J Black; Judith D Auerbach; Fulvia Veronese; Kimberly A Struble; Laura Cheever; Michael Johnson; Lynn A Paxton; Ida M Onorato; Alan E Greenberg
Journal:  MMWR Recomm Rep       Date:  2005-01-21

2.  A Cross-Sectional Online Survey of HIV Pre-Exposure Prophylaxis Adoption Among Primary Care Physicians.

Authors:  Oni J Blackstock; Brent A Moore; Gail V Berkenblit; Sarah K Calabrese; Chinazo O Cunningham; David A Fiellin; Viraj V Patel; Karran A Phillips; Jeanette M Tetrault; Minesh Shah; E Jennifer Edelman
Journal:  J Gen Intern Med       Date:  2016-10-24       Impact factor: 5.128

3.  [Non-occupational post-exposure HIV prophylaxis. Knowledge and practices among physicians and groups with risk behavior].

Authors:  Jesús Almeda; Alejandro Allepuz; Betty-Germaine Simon; Juan Antonio Blasco; Anna Esteve; Jordi Casabona i Barbarà
Journal:  Med Clin (Barc)       Date:  2003-09-20       Impact factor: 1.725

4.  Post-exposure prophylaxis after non-occupational HIV exposure: impact of recommendations on physicians' experiences and attitudes.

Authors:  Anne Laporte; Nathalie Jourdan; Elisabeth Bouvet; Franck Lamontagne; Josiane Pillonel; Jean-Claude Desenclos
Journal:  AIDS       Date:  2002-02-15       Impact factor: 4.177

5.  Cost-effectiveness of HIV postexposure prophylaxis following sexual or injection drug exposure in 96 metropolitan areas in the United States.

Authors:  Steven D Pinkerton; Jeffrey N Martin; Michelle E Roland; Mitchell H Katz; Thomas J Coates; James O Kahn
Journal:  AIDS       Date:  2004-10-21       Impact factor: 4.177

Review 6.  Non-occupational postexposure prophylaxis for HIV: a systematic review.

Authors:  J Bryant; L Baxter; S Hird
Journal:  Health Technol Assess       Date:  2009-02       Impact factor: 4.014

7.  [Chinese guidelines for diagnosis and treatment of HIV/AIDS (2018)].

Authors: 
Journal:  Zhonghua Nei Ke Za Zhi       Date:  2018-12-01

8.  A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group.

Authors:  D M Cardo; D H Culver; C A Ciesielski; P U Srivastava; R Marcus; D Abiteboul; J Heptonstall; G Ippolito; F Lot; P S McKibben; D M Bell
Journal:  N Engl J Med       Date:  1997-11-20       Impact factor: 91.245

9.  Announcement: Updated Guidelines for Antiretroviral Postexposure Prophylaxis after Sexual, Injection-Drug Use, or Other Nonoccupational Exposure to HIV - United States, 2016.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2016-05-06       Impact factor: 17.586

10.  HIV prescriptions on the frontlines: Primary care providers' use of antiretrovirals for prevention in the Southeast United States, 2017.

Authors:  Kirk D Henny; Christopher C Duke; Kate Buchacz; John T Brooks; Taraz Samandari; Madeline Y Sutton
Journal:  Prev Med       Date:  2019-10-31       Impact factor: 4.018

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.